145 related articles for article (PubMed ID: 18180806)
1. Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse?
Greco C; Cascini GL; Tamburrini O
Prostate Cancer Prostatic Dis; 2008; 11(2):121-8. PubMed ID: 18180806
[TBL] [Abstract][Full Text] [Related]
2. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
3. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
4. [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].
Moussaid Y; Bonardel G; Jacob J; Métivier D; Gontier E; Bauduceau O; Durand X; Fayolle M; Houlgatte A; Foehrenbach H; Védrine L; Chargari C
Cancer Radiother; 2013; 17(4):259-64. PubMed ID: 23702489
[TBL] [Abstract][Full Text] [Related]
5. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography.
Breeuwsma AJ; Pruim J; van den Bergh AC; Leliveld AM; Nijman RJ; Dierckx RA; de Jong IJ
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):160-4. PubMed ID: 19783375
[TBL] [Abstract][Full Text] [Related]
6. Contribution of
Gómez-de la Fuente FJ; Martínez-Rodríguez I; de Arcocha-Torres M; Quirce R; Jiménez-Bonilla J; Martínez-Amador N; Banzo I
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(3):156-162. PubMed ID: 29137875
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility and therapeutic impact of PET/CT [
Sánchez N; Valduvieco I; Ribal MJ; Campos F; Casas F; Nicolau C; Salvador R; Mellado B; Jorcano S; Fuster D; Paredes P
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):284-291. PubMed ID: 32467000
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
9. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.
Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383
[TBL] [Abstract][Full Text] [Related]
11. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
12. [11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma.
Reske SN; Moritz S; Kull T
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):430-9. PubMed ID: 23069922
[TBL] [Abstract][Full Text] [Related]
13. [Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment].
Cochet A; Kanoun S; Humbert O; Walker PM; Cormier L; Créhange G; Brunotte F
Cancer Radiother; 2014 Oct; 18(5-6):509-16. PubMed ID: 25195114
[TBL] [Abstract][Full Text] [Related]
14. [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen.
Giovacchini G; Picchio M; Garcia-Parra R; Mapelli P; Briganti A; Montorsi F; Gianolli L; Messa C
J Urol; 2013 Jan; 189(1):105-10. PubMed ID: 23164385
[TBL] [Abstract][Full Text] [Related]
15. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM
Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572
[TBL] [Abstract][Full Text] [Related]
16. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
[TBL] [Abstract][Full Text] [Related]
17. [18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy - a preliminary study.
Henninger B; Vesco P; Putzer D; Kendler D; Loizides A; Bale RJ; Virgolini IJ
Nucl Med Commun; 2012 Aug; 33(8):889-94. PubMed ID: 22692582
[TBL] [Abstract][Full Text] [Related]
18. Imaging of Prostate Cancer Using
Castellucci P; Ceci F; Fanti S
PET Clin; 2017 Apr; 12(2):137-143. PubMed ID: 28267448
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of PET scans in diagnosing recurrent prostate cancer. Prostate with PSA level < 5 ng/ml].
Rioja Zuazu J; Rodríguez M; Rincón Mayans A; Sansi AS; Zudaire Bergera JJ; Martínez-Monge R; Richter JA; Berián Polo JM
Actas Urol Esp; 2009 Sep; 33(8):844-52. PubMed ID: 19900376
[TBL] [Abstract][Full Text] [Related]
20. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography.
Karnes RJ; Murphy CR; Bergstralh EJ; DiMonte G; Cheville JC; Lowe VJ; Mynderse LA; Kwon ED
J Urol; 2015 Jan; 193(1):111-6. PubMed ID: 25150640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
